Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011002408 - NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA

Publication Number WO/2011/002408
Publication Date 06.01.2011
International Application No. PCT/SE2010/050760
International Filing Date 02.07.2010
IPC
C07D 401/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
A61K 31/4178 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07D 233/88 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
88Nitrogen atoms, e.g. allantoin
C07D 403/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
CPC
C07D 233/88
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
88Nitrogen atoms, e.g. allantoin
C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 401/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
Applicants
  • ASTRAZENECA AB [SE]/[SE] (AllExceptUS)
  • BLID, Jan [SE]/[SE] (UsOnly)
  • GINMAN, Tobias [SE]/[SE] (UsOnly)
  • GRAVENFORS, Ylva [SE]/[SE] (UsOnly)
  • KARLSTRÖM, Sofia [SE]/[SE] (UsOnly)
  • KIHLSTRÖM, Jacob [SE]/[SE] (UsOnly)
  • KOLMODIN, Karin [SE]/[SE] (UsOnly)
  • LINDSTRÖM, Johan [SE]/[SE] (UsOnly)
  • RAHM, Fredrik [SE]/[SE] (UsOnly)
  • SUNDSTRÖM, Marie [SE]/[SE] (UsOnly)
  • SWAHN, Britt-Marie [SE]/[SE] (UsOnly)
  • VIKLUND, Jenny [SE]/[SE] (UsOnly)
  • VON BERG, Stefan [DE]/[SE] (UsOnly)
  • VON KIESERITZKY, Fredrik [SE]/[SE] (UsOnly)
Inventors
  • BLID, Jan
  • GINMAN, Tobias
  • GRAVENFORS, Ylva
  • KARLSTRÖM, Sofia
  • KIHLSTRÖM, Jacob
  • KOLMODIN, Karin
  • LINDSTRÖM, Johan
  • RAHM, Fredrik
  • SUNDSTRÖM, Marie
  • SWAHN, Britt-Marie
  • VIKLUND, Jenny
  • VON BERG, Stefan
  • VON KIESERITZKY, Fredrik
Agents
  • ASTRAZENECA INTELLECTUAL PROPERTY
Priority Data
61/222,53502.07.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA
(FR) NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE LA NEURODÉGÉNÉRESCENCE ASSOCIÉE À DES MALADIES, TELLES QUE LA MALADIE D'ALZHEIMER OU LA DÉMENCE
Abstract
(EN)
The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
(FR)
La présente invention concerne de nouveaux composés de formule (I) et leurs compositions pharmaceutiques. De plus, la présente invention concerne des procédés thérapeutiques pour le traitement et/ou la prévention de pathologies associées à Aβ telles que le syndrome de Downs, une angiopathie β-amyloïde telle que, mais non limitée à, l'angiopathie amyloïde cérébrale ou une hémorragie cérébrale héréditaire, des troubles associés à un trouble cognitif tel que, mais non limité à, un TCL (« trouble cognitif léger »), la maladie d'Alzheimer, la perte de mémoire, les symptômes de déficit d'attention associés à la maladie d'Alzheimer, la neurodégénérescence associée à des maladies telles que la maladie d'Alzheimer ou la démence y compris la démence d'origine vasculaire et dégénérative mixte, la démence présénile, la démence sénile et la démence associée à la maladie de Parkinson, la paralysie supranucléaire progressive ou la dégénérescence cortico-basale.
Latest bibliographic data on file with the International Bureau